hubXchange

We are delighted to be speaking and sponsoring a keynote at the AI in Drug Discovery hubXchange this Thursday! Join Brian Gilman, EVP of Corporate Market at Digital Science for this opening address and keynote presentation: 👉The Future of AI in Pharma: Accelerating Research Workflows with GenAI 🗓️ Oct 31 @ 8:30am EST 📍Hyattsville, MD In this keynote presentation, we will explore the transformative impact of Generative AI (GenAI) on research workflows and systematic literature reviews within the pharmaceutical industry. Traditional AI technologies like natural language processing and machine learning have long been used to streamline screening and data synthesis. Recent advances in Generative AI and multimodal capabilities offer new opportunities to accelerate workflows at every stage. But despite the promise of GenAI, the human perspective remains crucial. We will discuss the evolving roles of researchers and the need to balance automation with human insight. To learn more: https://ow.ly/WzJB50TVA5t

🔬🌐 Calling all Biotherapeutics Experts! 🌐🔬 Join us for a high-impact roundtable discussion, "What are the differences between BsAb process development and standard mAbs?" on November 18, 2024, at the Antibody Therapeutics Xchange in Brussels! Dive deep into the latest insights with industry expert Alessandra Basso Global Sales & Marketing Director, Life Science at Sunresin New Materials Co. Ltd. 🗓 Session Details: 📅 Date: 18 Nov 2024 ⏰ Time: 11:25 - 12:25 📍 Track: Bi/Multispecifics 🔑 Key topics include: 💡 The driving forces behind the rise of BsAbs in the market 🛠️ Process development and DSP distinctions for BsAbs vs. mAbs 🔍 Managing impurity profiles and tackling residual homodimers 🔭 Future predictions for the BsAb landscape over the next decade With a Master’s and PhD in Pharmaceutical Sciences, an EMBA, 80+ publications, and 3 patents, Alessandra’s expertise spans specialty resins, biocatalysis, chromatography, and more. Don’t miss her insights on this critical aspect of antibody therapeutics! 📢 Register today to stay at the cutting edge of biotherapeutic advancements! 🌍 https://lnkd.in/eZDVBH-x Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. 💊 #AntibodyTherapeutics #BiMultispecifics #ProcessDevelopment #Biotechnology #LifeSciences #BsAbs #PharmaceuticalScience #Biotherapeutics #DrugDevelopment #DSP #ImpurityManagement #BiotechInnovation #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

We’re proud to have sponsored the Antibody Therapeutics hubXchange – Maryland 2024, where our team connected with industry leaders and innovators. Our keynote presentation by Rachel Fong, highlighted: 🔬 How cell-based protein arrays like the Membrane Proteome Array (MPA) are transforming antibody specificity testing. ⚙️ The impact of off-target binding and how it contributes to drug attrition and patient risks. Integral Molecular’s attendees, Kris Raghavan, Ph.D., Ileine Sanchez, PhD, and Rachel Fong, engaged in meaningful discussions throughout the event, sharing insights and learning from fellow experts. In case you missed us ➡ https://lnkd.in/gksnx4x #AntibodyTherapeutics #Biotech #Pharma #DrugDevelopment #AntibodyEngineering #Polyspecificity #IntegralMolecular #MembraneProteomeArray #AntibodySpecificity #TherapeuticInnovation #PharmaceuticalResearch #Biopharma #AntibodyDiscovery #MPATechnology #BiotechnologyEvent #TherapeuticDevelopment #TeamIntegralMolecular

🔬✨ Join us at the Antibody Therapeutics Xchange - Europe 2024 in Brussels for an immersive roundtable discussion on Early Immunogenicity Risk Assessment and Functional Testing of Biotherapeutics! 🗓 Date: 18 November 2024 ⏰ Time: 11:25 - 12:25 📍 Track: Formats & Scaffolds (Lead Identification & Optimization Topic) Led by Chloé Ackaert, Senior Scientist at IQVIA Laboratories– In Vitro Immunology, this discussion will uncover cutting-edge methods to advance safer, more effective biotherapeutics. Chloé brings a wealth of expertise in immunogenicity, with a background as a pharmacist and a PhD in allergen immunogenicity, plus experience in both industry and academia working on Nanobody development. 🔑 Key Topics Include: 🧬 In silico and in vitro immunogenicity assessment as a de-risking strategy 🧪 Approaches to mitigate unwanted immunogenicity of therapeutic proteins 💉 Designing low immunogenic antibodies 🔍 In vitro functional testing of lead candidates Don’t miss this chance to connect with leading experts and dive into innovative solutions for biotherapeutic development. Register today and be part of this important conversation! https://lnkd.in/eqRcCaBg Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. 💊 #Immunogenicity #Biotherapeutics #AntibodyTherapeutics #BiotechInnovation #DrugDevelopment #LeadOptimization #Immunology #XchangeEurope2024 #ProteinEngineering #PharmaInnovation #LifeSciences #Therapeutics #BiotechRoundtable #AntibodyEngineering #DrugSafety #Biopharmaceuticals #ScientificInnovation #ClinicalResearch #Immunotherapy #Biologics #TherapeuticProteins #InVitroTesting #DrugDiscovery #RoundtableNetworking #TherapeuticsXchange #LifeScience #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

🔬 Are you navigating the complexities of bispecific antibody production? Join us for a groundbreaking Poster Presentation at the Antibody Therapeutics Xchange - Europe, where we’ll explore cutting-edge advancements in overcoming one of the most significant challenges in bispecific antibody engineering. 📅 Date: 18 Nov 2024 🕒 Time: 16:30 - 17:00 📍 Location: Bi/Multispecifics Track, Antibody Therapeutics Xchange – Brussels REGISTER FOR FREE: https://lnkd.in/emn5iUJy Poster Presentation: Solving the Bispecific Antibody Mispairing Challenge in Preclinical R&D What You'll Learn Successfully producing bispecific antibodies requires the precise assembly of multiple peptide chains to achieve a stable heterodimeric structure. While several mutation strategies promote the correct pairing of heavy chain dimers, fewer approaches address the complex pairing requirements for both heavy and light chains. Enter bYlok® bispecific pairing technology, developed by Lonza. This innovative approach leverages engineered disulfide bridges within bispecific molecules, providing a revolutionary solution to mispairing challenges. Key takeaways include: How bYlok® technology ensures >95% purity in heterodimers using a single Protein A-based purification process The distinct advantages of engineered disulfide bridges in improving antibody stability and efficacy Real-world applications of bYlok® technology for consistent and efficient preclinical R&D Industry Expert: Desmond Schofield, Chief Business Officer of evitria AG With a career devoted to removing roadblocks in scientific discovery, Des brings unparalleled insights to the challenges and innovations in antibody development. From his early hands-on work in the lab to his leadership at Sartorius Stedim and now at Evitria, he’s always focused on empowering scientists to prioritize discovery over time-consuming tasks. His strategic mindset and dedication to environmentally sustainable solutions set him apart as a true leader in the industry. Secure your place now to stay ahead in bispecific antibody research, streamline your R&D workflows, and contribute to a future where science progresses seamlessly, sustainably, and with greater speed. 🌍 Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. 💊 #AntibodyEngineering #BispecificAntibodies #BiologicsInnovation #AntibodyTherapeutics #Immunotherapy #Biopharma #RNDInnovation #BiotechNews #SustainableScience #Biotherapeutics #ProteinEngineering #PreclinicalResearch #ScienceInnovation #AntibodyProduction #PharmaRND #AntibodyDevelopment #TherapeuticsXchange #LifeScience #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

🔬 Advancing Drug Discovery Through AI: Don’t Miss Alexis Molina’s Session! 🚀 Meet Alexis Molina, Director of AI at Nostrum Biodiscovery, at the AI in Drug Discovery Xchange Europe 2024! Join him on November 21st in Brussels for an eye-opening session on leveraging ultra-large databases to optimize lead generation. 🌐💊 Save your spot and register now! 🔗 https://lnkd.in/eCh_M_FJ 🎯 Session Focus: Informed Lead Generation from Screening Ultra-Large Databases 🔍 Rapid Screening: Analyzes billions of molecules within hours using advanced deep learning. 📊 Smart Selection: Precision-driven model trained on just 0.001% of the library to predict top candidates. 💡 Explainable AI: Highlights key molecular features for optimized lead identification. 🔄 Efficient Active Learning: Continuously refines the model for better results. 🌟 Why It Matters: With extensive experience in protein modeling and drug interaction prediction, Alexis has been at the forefront of AI-driven molecular research, advancing his career from Barcelona Supercomputing Center to Nostrum Biodiscovery. Now, he leads innovative screening and optimization strategies that are setting new standards in drug discovery. 🔬✨ 🔹 Event Details 📅 Date: Thursday, November 21, 2024 📍 Location: DoubleTree by Hilton, Brussels City Be part of this interactive, networking-rich experience designed to fuel innovation in pharmaceuticals and biotech! 🌍🤖💼 Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. 💊 #AIinDrugDiscovery #DrugDiscoveryInnovation #PharmaAI #MolecularModeling #LeadOptimization #HighThroughputScreening #ExplainableAI #BiotechTrends #AIinPharma #LifeSciences #DrugDevelopment #PharmaNetworking #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

✈️ Are you attending Antibody Therapeutics Xchange in Maryland on October 28? Don’t miss an exclusive spotlight presentation by Sundee Dees, Ph.D., Senior Manager of Business Development at WuXi Biologics’ CRO Services, where she will discuss innovative production strategies for Fab, ScFv, and VHH, with tailored engineering approaches for each molecule. Additionally, join our roundtable discussion on “Emerging Opportunities and Challenges in Bi-/Multi-Specific Antibody Drug Development,” led by Dr. Zeck Huang, Senior Director & Nonclinical Lead at WuXi Biologics. Want to connect with us? Schedule a meeting with our Business Development team here: ▶️ https://lnkd.in/eAg4H58n. #AntibodyTherapeutics #DrugDevelopment #DrugDiscovery #AntibodyProduction

Antibody Therapeutics Market | Growing at CAGR 14.1% 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭  https://lnkd.in/dy8Nauq6 The size of global antibody therapeutics market in terms of revenue was estimated to be worth $247.3 billion in 2023 and is poised to reach $479.0 billion by 2028, growing at a CAGR of 14.1% from 2023 to 2028 Companies From the Market Chinese Antibody Society Agenus Telesis Bio      BigHat Biosciences   Abpro     Lumen Bioscience      Pionyr Immunotherapeutics      Genmab    HARBOUR BIOMED   Star Therapeutics Zymeworks Inc. Abilita Therapeutics, Inc. Prestige Biopharma Group (Prestige Biopharma / Prestige Biologics)    Aethon Therapeutics Neurimmune AG  RenBio   Antiverse   Apexigen    Yumab GmbH      Humabs BioMed, subsidiary of Vir Biotechnology      DJS Antibodies hubXchange   Genor BioPharma Co., Ltd.    Sporos Bioventures  ABL Bio Inc.

Next week, Indranath Ghosh, Ph.D., our Director of Medicinal Chemistry, will participate in hubXchange's AI in Drug Discovery Xchange Maryland 2024. Dr. Ghosh will lead a roundtable discussion on using AI to reduce the timeline of lead generation to optimization—a game-changing approach in drug discovery.    Learn more here: https://lnkd.in/gv9BT_QZ     #Biotech #Innovation #DrugDiscovery #AI 

⏳ The Countdown is On – Just 3 Days Left! ⏳ Time is running out to join us at the Maryland Xchanges! Don't miss this rare opportunity to dive into groundbreaking discussions with leading experts, explore the latest industry advancements, and expand your professional network. 🌐 There are still a few spots left—don’t wait until it’s too late! 🟡 Antibody Therapeutics Xchange - October 28 - https://lnkd.in/egGdd57Z 🟣 Immunotherapies Xchange - October 29 - https://lnkd.in/eWz-J6gw 🟠 Oligonucleotide Therapeutics Xchange - October 30 - https://lnkd.in/et63qfjs 🔵 AI in Drug Discovery Xchange - October 31 - https://lnkd.in/eNsbf9cF This is your chance to gain real-world insights and network with the best in the industry. If you're ready to make a difference, grab one of the last remaining seats today! 💼 Register now before it's too late! 💥 #AntibodyTherapeutics #Immunotherapies #OligonucleotideTherapeutics #AIinDrugDiscovery #Biotech #Pharma #DrugDiscovery #Biologics #LifeSciences #Innovation #Networking #Pharmaceuticals #MarylandEvents #Xchange #Therapeutics